Canada
HBV elimination goal
Yes
Year of HBV elimination goal
No data
HBV Action Plan
Yes
HCV elimination goal
Yes
Year of HCV elimination goal
No data
HCV Action Plan
Yes
Prevalence
Prevalence of chronic HBV (HBsAg+) (%)
0.6
Prevalence of chronic HBV (HBsAg+), Children < 5 yrs
No data
Prevalence
Prevalence of chronic HCV (RNA+/cAg) (%)
0.54
Prevalence of chronic HCV (RNA+/cAg), Persons who inject drugs
No data
Mortality
Mortality
Diagnosed & treated
Proportion of persons living with HBV diagnosed (%)
71
Proportion of diagnosed persons receiving appropriate HBV treatment (%) (among those eligible)
No data
Diagnosed & treated
Proportion of persons living with HCV diagnosed (%)
76
Proportion of diagnosed persons who have initiated HCV treatment (%)
No data
HepB newborn vaccination
Coverage of HepB birth dose (%)
No data
Harm reduction
Key policy indicators
HBV screening recommendations for pregnant women
Adopted
No patient co-pays for HBsAg testing
No Data
Key policy indicators
National policy for harm reduction for persons who inject drugs
Adopted
No patient co-pays for anti-HCV testing
Adopted
Simplified HCV care: Non-specialists can prescribe treatment
Not Adopted
Year | Value | Type | Source |
---|
Equity
Indicator | Status | Notes |
---|---|---|
Decriminalization of drug use | Not Adopted |
|
National anti-discrimination law protecting persons living with hepatitis | Partially Adopted |
|
National policy for adult HBV vaccination | Adopted |
|
National policy for harm reduction for persons who inject drugs | Adopted |
|
National policy for syringe exchange in federal prisons | Adopted |
|
National strategy addresses key populations | Adopted |
|
Prevention of mother-to-child transmission
Indicator | Status | Notes |
---|---|---|
Elimination of HBV mother to child transmission goal | Yes |
|
HBV screening recommendations for pregnant women | Adopted |
|
Universal HepB birth dose policy within 24 hrs of birth | Partially Adopted |
|
Strategic information
Indicator | Status | Notes |
---|---|---|
Estimates of HBV economic burden | Adopted |
|
National HBV prevalence survey within last 5 years | Adopted |
|
Routine official reporting of HBV incidence | Adopted |
|
Routine official reporting of HBV mortality | Not Adopted |
|
System to monitor HBV diagnosis and treatment | Partially Adopted |
|
Financing
Indicator | Status | Notes |
---|---|---|
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction | Not Applicable |
|
Public budget line for HBV testing and treatment | Adopted |
|
National planning
Indicator | Status | Notes |
---|---|---|
HBV Action Plan | Yes |
|
HBV elimination goal | Yes |
|
Screening
Indicator | Status | Notes |
---|---|---|
HBV age-based or birth-cohort screening recommendations | Adopted |
|
HBV risk-based screening recommendations | Adopted |
|
HBV universal screening recommendations | Not Adopted |
|
No patient co-pays for HBsAg testing | No Data |
|
Access to testing and medicines
Indicator | Status | Notes |
---|---|---|
Licensed point-of-care PCR testing to detect HBV | Not Adopted |
|
Treatment
Indicator | Status | Notes |
---|---|---|
National HBV treatment guidelines | No Data |
|
Simplified HBV care: No treatment co-pays | Adopted |
|
Simplified HBV care: Treatment and monitoring algorithm for primary care providers | No Data |
|
Year | Value | Type | Source |
---|
Year | Value | Type | Source |
---|
Equity
Indicator | Status | Notes |
---|---|---|
Decriminalization of drug use | Not Adopted |
|
Decriminalization of possession of syringes and paraphernalia | Adopted |
|
National anti-discrimination law protecting persons living with hepatitis | Partially Adopted |
|
National policy for harm reduction for persons who inject drugs | Adopted |
|
National policy for syringe exchange in federal prisons | Adopted |
|
National strategy addresses key populations | Adopted |
|
Access to testing and medicines
Indicator | Status | Notes |
---|---|---|
Eligible for HCV generic medicines | Not Eligible |
|
Licensed point-of-care PCR testing to detect HCV | Not Adopted |
|
Registration of HCV generic medicines | Not Applicable |
|
Registration of HCV originator medicines | Adopted |
|
Strategic information
Indicator | Status | Notes |
---|---|---|
Estimates of HCV economic burden | Adopted |
|
National HCV prevalence survey within last 5 years | Adopted |
|
Routine official reporting of HCV incidence | Adopted |
|
Routine official reporting of HCV mortality | Not Adopted |
|
System to monitor HCV diagnosis and treatment | Partially Adopted |
|
Financing
Indicator | Status | Notes |
---|---|---|
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction | Not Applicable |
|
Public budget line for HCV testing and treatment | Adopted |
|
National planning
Indicator | Status | Notes |
---|---|---|
HCV Action Plan | Yes |
|
HCV elimination goal | Yes |
|
Screening
Indicator | Status | Notes |
---|---|---|
HCV age-cohort or birth-cohort screening recommendations | Not Adopted |
|
HCV risk-based screening recommendations | Adopted |
|
HCV universal screening recommendations | Not Adopted |
|
No patient co-pays for anti-HCV testing | Adopted |
|
Prevention of mother-to-child transmission
Indicator | Status | Notes |
---|---|---|
HCV screening recommendations for pregnant women | Partially Adopted |
|
Treatment
Indicator | Status | Notes |
---|---|---|
National HCV treatment guidelines | Developed |
|
Simplified HCV care: Less than 2 clinic visits during treatment | Adopted |
|
Simplified HCV care: No fibrosis restrictions | Partially Adopted |
|
Simplified HCV care: No genotyping requirements | Partially Adopted |
|
Simplified HCV care: No sobriety restrictions | Adopted |
|
Simplified HCV care: No treatment co-pays | Partially Adopted |
|
Simplified HCV care: Non-specialists can prescribe treatment | Not Adopted |
|
Year | Value | Type | Source |
---|
Page last updated: 31 January 2024